Home Cart Sign in  
Chemical Structure| 883065-90-5 Chemical Structure| 883065-90-5

Structure of BI-78D3
CAS No.: 883065-90-5

Chemical Structure| 883065-90-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.

Synonyms: JNK Inhibitor X; c-Jun N-terminal Kinase Inhibitor X

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BI-78D3

CAS No. :883065-90-5
Formula : C13H9N5O5S2
M.W : 379.37
SMILES Code : [O-][N+](=O)C1=CN=C(SC2=NNC(=O)N2C2=CC3=C(OCCO3)C=C2)S1
Synonyms :
JNK Inhibitor X; c-Jun N-terminal Kinase Inhibitor X
MDL No. :MFCD01313575
InChI Key :QFRLDZGQEZCCJZ-UHFFFAOYSA-N
Pubchem ID :2747117

Safety of BI-78D3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BI-78D3

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK1

    JNK, IC50:280 nM

  • JNK

    JNK, IC50:280 nM

  • JNK2

    JNK, IC50:280 nM

  • JNK3

    JNK, IC50:280 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A375 human melanoma cells 1 µM 1 hour Inhibition of ERK phosphorylation and downstream signaling PMC6863825
HEK293 cells 25 µM 2 hours Covalent modification of ERK2 by BI-78D3 PMC6863825
Primary human AML cells (IDH1R132C) 5 nM 24 hours Inhibition of R-2HG production PMC5940517
RL95-2 human endometrial cancer cells 50 µM 1 hour BI-78D3 significantly abolished the PAE-induced increase in p-JNK expression but did not significantly affect the anti-proliferative effect of PAE PMC5740769
Porcine retinal arterioles 7 μM 2 hours To investigate the effect of acute hyperglycemia on endothelium-dependent dilation of retinal arterioles, BI-78D3 preserved the impaired vasodilation induced by high glucose via inhibition of JIP1/JNK signaling pathway. PMC5015966
Human prostate smooth muscle cells 30 μM 2 hours To investigate the effect of BI-78D3 on noradrenaline- and phenylephrine-induced contractions of prostate strips, results showed that BI-78D3 significantly inhibited these contractions PMC3402815
Osteoarthritis human MSCs 1 μM 24 hours To investigate the effect of BI-78D3 on Naproxen-induced COL10A1 expression. Results showed that BI-78D3 significantly suppressed Naproxen-induced COL10A1 expression. PMC4292866
Normal human MSCs 1 μM 24 hours To investigate the effect of BI-78D3 on Naproxen-induced COL10A1 expression. Results showed that BI-78D3 significantly suppressed Naproxen-induced COL10A1 expression. PMC4292866
HeLa cells 12.4 µM (EC50) 60 min pretreatment, 30 min TNF-α stimulation Inhibits TNF-α stimulated c-Jun phosphorylation PMC2567907
HoxA9-IDH1R132C 45 nM 8 days Inhibition of intracellular R-2HG production PMC5940517
HoxA9-IDH1R132H 60 nM 8 days Inhibition of intracellular R-2HG production PMC5940517

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice A375 human melanoma xenograft model Intraperitoneal injection 15 mg/kg Daily for 10 days Suppression of tumor growth and ERK phosphorylation PMC6863825
Pigs Streptozotocin-induced diabetic model Intraluminal administration 7 μM Single dose, lasting 2 hours To investigate the effect of chronic hyperglycemia on endothelium-dependent dilation of retinal arterioles, BI-78D3 restored the impaired vasodilation induced by high glucose via inhibition of JIP1/JNK signaling pathway. PMC5015966
C57BL/6 mice ConA-induced liver injury model Intravenous injection 10 mg/kg Single dose, evaluated after 7.5 hours Significantly reduced serum ALT levels, blocked ConA-induced liver damage PMC2567907

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.18mL

2.64mL

1.32mL

26.36mL

5.27mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories